BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:03 PM
 | 
May 28, 2010
 |  BC Extra  |  Company News

FDA questions motavizumab safety

FDA questioned the risk-benefit profile of motavizumab in briefing documents posted ahead of Wednesday's Antiviral Drugs Advisory Committee meeting to discuss the humanized RSV antibody from MedImmune LLC to prevent serious respiratory syncytial virus (RSV). The documents noted that motavizumab has...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >